American Society of Hematology

Figure 5.

$One-way sensitivity analyses of 2nd-line CAR-T in all patients. (A) One-way sensitivity analysis of the 2-year EFS in late-relapsed DLBCL (second-line CAR-T in all patients with RR-DLBCL compared with second-line CAR-T in primary refractory/early relapse patients and SOC in late relapse patients). In this analysis, we vary the 2-year EFS with second-line CAR-T in patients with late-relapsed DLBCL while keeping other parameters constant to identify scenarios in which CAR-T would be cost-effective for all patients with RR-DLBCL in the second-line setting. It found that second-line CAR-T is cost-effective if it has a 2-year EFS ≥58.6% (green dotted lines) at a WTP of $150 000. (B) One-way sensitivity analysis of the 5-year EFS in late-relapsed DLBCL (second-line CAR-T in all patients with RR-DLBCL compared with second-line CAR-T in primary refractory/early relapse patients and SOC in late relapse patients). In this analysis, we vary the 5-year EFS with second-line CAR-T in patients with late-relapsed DLBCL while keeping other parameters constant to identify scenarios in which CAR-T would be cost-effective for all patients with RR-DLBCL in the second-line setting. It shows that second-line CAR-T is cost-effective if it has a 5-year EFS ≥47.2% (green dotted lines) at a WTP of $150 000.$

One-way sensitivity analyses of 2nd-line CAR-T in all patients. (A) One-way sensitivity analysis of the 2-year EFS in late-relapsed DLBCL (second-line CAR-T in all patients with RR-DLBCL compared with second-line CAR-T in primary refractory/early relapse patients and SOC in late relapse patients). In this analysis, we vary the 2-year EFS with second-line CAR-T in patients with late-relapsed DLBCL while keeping other parameters constant to identify scenarios in which CAR-T would be cost-effective for all patients with RR-DLBCL in the second-line setting. It found that second-line CAR-T is cost-effective if it has a 2-year EFS ≥58.6% (green dotted lines) at a WTP of $150 000. (B) One-way sensitivity analysis of the 5-year EFS in late-relapsed DLBCL (second-line CAR-T in all patients with RR-DLBCL compared with second-line CAR-T in primary refractory/early relapse patients and SOC in late relapse patients). In this analysis, we vary the 5-year EFS with second-line CAR-T in patients with late-relapsed DLBCL while keeping other parameters constant to identify scenarios in which CAR-T would be cost-effective for all patients with RR-DLBCL in the second-line setting. It shows that second-line CAR-T is cost-effective if it has a 5-year EFS ≥47.2% (green dotted lines) at a WTP of $150 000.

This Feature Is Available To Subscribers Only